Key result
Fluvastatin lowers LDL-C ~21% but fails to reduce AECG ischemia or post-MI events.
Why the study?
Residual ischaemia following acute myocardial infarction is related to adverse outcomes, but the effect of early statin therapy on ischaemia is unknown.
Does fluvastatin reduce ischemia on AECG or major clinical events in patients following acute myocardial infarction?
Comparison
Fluvastatin 80 mg daily vs placebo
Design
Randomized, placebo-controlled, double-blind, parallel study
Follow-up
12 months
Authors
Loading...
Early fluvastatin post-AMI does not reduce AECG ischemia or events; challenges ischemia-reduction hypothesis and supports alternative research priorities.
RCT (n=540)
Double-blind
Parallel
Does fluvastatin reduce ischemia on AECG or major clinical events in patients following acute myocardial infarction?
Early initiation of fluvastatin 80 mg daily did not significantly reduce AECG ischemia or major clinical events at 1 year post-AMI, though the study was underpowered due to low baseline ischemia rates.
An Ho Liem (2002) conducted an RCT in Acute myocardial infarction (AMI) (n=540). Fluvastatin vs. Placebo was evaluated on Ischaemia on ambulatory electrocardiographic (AECG) monitoring and major clinical events. Fluvastatin 80 mg daily reduced LDL-C by 21% (P<0.001 vs placebo) but did not significantly affect AECG ischaemia or major clinical events in the first year after acute myocardial infarction.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: